A retrospective, single center study analysing strategy of Pre-transplant myeloid and immune suppression, upfront plerixafor mobilization and post-transplant cyclophosphamide in sickle cell disease
Latest Information Update: 18 Sep 2020
At a glance
- Drugs Antithymocyte globulin (Primary) ; Azathioprine (Primary) ; Busulfan (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Fludarabine (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Hydroxycarbamide (Primary) ; Mycophenolate mofetil (Primary) ; Mycophenolate sodium (Primary) ; Plerixafor (Primary) ; Sirolimus (Primary) ; Thiotepa (Primary) ; Antimalarials; Cotrimoxazole; Fluconazole; Levetiracetam; Penicillins; Valaciclovir
- Indications Graft-versus-host disease; Sickle cell anaemia; Transplant rejection
- Focus Adverse reactions; Therapeutic Use
- 18 Sep 2020 New trial record
- 15 Sep 2020 Results published in the Bone Marrow Transplantation